Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
è¬çè¬å¯©çº 1225第 13å·
什åïŒå¹Ž 12 æ 25 æ¥
åéœéåºçè¡ç䞻管éšïŒå±ïŒé· 殿
åçåŽåçå»è¬ã»ç掻è¡çå±å»è¬å審æ»ç®¡ç課é·
ïŒ å ¬ å° ç ç¥ ïŒ
Biopharmaceutics Classification SystemïŒBCSïŒã«åºã¥ããã€ãª
ãŠã§ãŒããŒã¬ã€ãã©ã€ã³ã«ã€ããŠ
å»è¬åèŠå¶èª¿ååœéäŒè°ïŒä»¥äžãICHããšãããïŒãçµç¹ãããå質ãå®å š
æ§åã³æå¹æ§ã®ååéã§ãããŒã¢ãã€ãŒãŒã·ã§ã³ã®ä¿é²ãå³ãããã®æŽ»åãè¡
ãããŠãããšããã§ãã
ä»è¬ãå»è¬åã®æ°èŠè£œé 販売æ¿èªç³è«åã³è£œé 販売æ¿èªäºé ã®äžéšå€æŽç³è«
ã«éããŠæ·»ä»ãã¹ãè³æã«é¢ããICHã«ãããåæäºé ãšããŠãæ°ãã«
ãBiopharmaceutics Classification SystemïŒBCSïŒã«åºã¥ããã€ãªãŠã§ãŒã
ãŒã¬ã€ãã©ã€ã³ããå¥æ·»ã®ãšããå®ããŸããã®ã§ãäžèšäºé ã埡äºç¥ã®äžã貎
管å é¢ä¿æ¥è çã«å¯Ÿãåšç¥æ¹åŸ¡é æ ®é¡ããŸãã
èš
ïŒïŒèæ¯
ããçç©åŠçåçæ§è©ŠéšïŒä»¥äžãBEè©ŠéšããšãããïŒã®å®æœãæžããããã
å¹ççãã€åççãªå»è¬åéçºãä¿é²ããããšãç®çã«ãICH ã«ãããåæ
ã«åºã¥ããè¿å¹Žã®ç§åŠã®é²æ©åã³çµéšãèžãŸããŠããBiopharmaceutics
Classification SystemïŒBCSïŒã«åºã¥ããã€ãªãŠã§ãŒããŒã¬ã€ãã©ã€ã³ãïŒä»¥
äžãæ¬ã¬ã€ãã©ã€ã³ããšãããïŒãå®ããããã
ïŒïŒæ¬ã¬ã€ãã©ã€ã³ã®èŠç¹
æ¬ã¬ã€ãã©ã€ã³ã¯ãBEè©Šéšãå®æœããããšãªããçç©åŠçåçæ§ã確èªã
ãææ³ãšããŠãBCSã«åºã¥ãããçç©åŠçåçæ§è©Šéšã®å é€ïŒãã€ãªãŠã§ãŒã
ãŒïŒãå®æœããããšã«ã€ããŠã補é 販売æ¿èªç³è«ã«ãããå®æœèŠä»¶ã®æéã瀺
ããã
ïŒïŒé©çšææ
æ¬ã¬ã€ãã©ã€ã³ã¯ã什åïŒå¹Ž 12æ 25æ¥ä»¥éã«è¡ãããå»è¬åã®æ°èŠè£œé 販
売æ¿èªç³è«åã³è£œé 販売æ¿èªäºé ã®äžéšå€æŽæ¿èªç³è«ã«ã€ããŠé©çšããããã
ããåŸçºå»è¬åã«ã€ããŠã¯ãæšæºè£œå€ã®åŠæ¹æ å ±ã®ææ¡ãå°é£ã§ããããšã
ããåœé¢ãæ¬ã¬ã€ãã©ã€ã³ã«åºã¥ãæ°èŠè£œé 販売æ¿èªç³è«ãè¡ãããšã¯å·®ãæ§
ãããããã
以äž
ICH M9 ã¬ã€ãã©ã€ã³
Biopharmaceutics Classification SystemïŒBCSïŒã«åºã¥ã
ãã€ãªãŠã§ãŒããŒ
ç®æ¬¡
1. ç·èš .................................................................................................................................................. 2
1.1. èæ¯ãšç®ç................................................................................................................................ 2
1.2 é©çšç¯å².................................................................................................................................... 2
2. åè¬ã®çç©è¬å€åŠåé¡ .................................................................................................................. 3
2.1. 溶解æ§........................................................................................................................................ 3
2.2. èééæ§.................................................................................................................................... 4
3. 補å€ã® BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒãžã®èŠä»¶ ..................................................................... 5
3.1. æ·»å å€........................................................................................................................................ 5
3.2. In vitro 溶åºè©Šéš....................................................................................................................... 7
4. ææžå ............................................................................................................................................ 10
5. çšèªé ............................................................................................................................................ 10
å¥æ·» IïŒCaco-2 现èãçšããèééæ§è©Šéšã«ãããçæäºé ......................................................... 11
å¥æ·» IIïŒæ·»å å€ã®éãã®è©äŸ¡ã«é¢ãã詳现æ å ± ............................................................................... 15
1. ç·èš
1.1. èæ¯ãšç®ç
åäžã®æå¹æåãå«æãã 2 ã€ã®è£œå€ã¯ãåãçšéã§æäžåŸã®ãã€ãªã¢ãã€ã©ããªãã£ïŒè¬
ç©åžåã®é床ãšéïŒãäºåã«èŠå®ããã蚱容é床å€å ã§ããã°ãçç©åŠçã«åçãšã¿ãªãã
ãããããã®é床å€ã¯ãæ²»çåŠçãªåçæ§ãããªãã¡å®å šæ§åã³æå¹æ§ãä¿èšŒããããã«èš
å®ããããããçç©åŠçåçæ§è©Šéšã§ã¯ãè¬ç©åžåã®éãšé床ãè©äŸ¡ããããã«ãäžè¬ã«äž»
èŠãªè¬ç©åæ ãã©ã¡ãŒã¿ã§ãã AUCïŒè¡äžæ¿åºŠ-æéæ²ç·äžé¢ç©ïŒãš CmaxïŒæé«è¡äžæ¿åºŠïŒã
䜿çšãããã
BCSïŒBiopharmaceutics Classification SystemïŒã«åºã¥ããã€ãªãŠã§ãŒããŒã¯ãããçç©åŠçå
çæ§è©Šéšã®å®æœãæžããããšãããªãã¡ããçç©åŠçåçæ§è©Šéšã®ä»£æ¿æ³ãæäŸããããšã
æå³ããŠãããããçç©åŠçåçæ§è©Šéšã¯ãæ²»çåŠçãªåçæ§ãåå㪠in vitro ããŒã¿ã«ãã£
ãŠæ£åœåã§ããã°ãå é€ãå¯èœãšèããããšãã§ãããBCS ã¯ãåè¬ã®æº¶è§£æ§åã³èééæ§
ã«åºã¥ãç§åŠçã¢ãããŒãã§ãããBCS ã¯ãåè¬ã以äžã® 4 ã€ã® BCS ã¯ã©ã¹ã® 1 ã€ã«åé¡ã
ãïŒ
ã¯ã©ã¹ IïŒé«æº¶è§£æ§ãé«èééæ§
ã¯ã©ã¹ IIïŒäœæº¶è§£æ§ãé«èééæ§
ã¯ã©ã¹ IIIïŒé«æº¶è§£æ§ãäœèééæ§
ã¯ã©ã¹ IVïŒäœæº¶è§£æ§ãäœèééæ§
ãã®ã¬ã€ãã³ã¹ã¯ãåè¬ã®çç©è¬å€åŠåé¡ãšè£œå€ã®çç©åŠçåçæ§è©Šéšã® BCS ã«åºã¥ããã
çç©åŠçåçæ§è©Šéšå é€ãè¡ãããã«æšå¥šããå 容ãæ瀺ãããã®ã§ããããªãã詳现ãã€
ååãªç§åŠçæ ¹æ ã«ãã£ãŠèª¬æããããšãå¯èœã§ããã°ãæ¬ã¬ã€ãã©ã€ã³ã«æèšãããŠããª
ãææ³ãèãæ¹ãå©çšã㊠BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®æŠå¿µã¯é©çšã§ããã
1.2 é©çšç¯å²
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã¯ãããã«ãããçç©åŠçåçæ§ãå®èšŒããããã«äœ¿çšã§ã
ããååœ/å°åã®èŠå¶ã«åŸã£ãäžã§ãäŸãã°åååãŸã§ã®éçºæ®µéã§äœ¿çšããã補å€éã®æ¯èŒ
æãæ¿èªåŸã®è£œå€å€æŽæãåŸçºå»è¬åã®ç³è«æãªã©ã«äœ¿çšã§ããã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã¯ãè¬ç©ãå šèº«åŸªç°ã«å°éããããšãç®çãšããå³æŸæ§ã®çµ
å£åºåœ¢è£œå€åã¯æžæ¿å€ã«ã®ã¿é©çšããããæ²»çæ¿åºŠåãçãè¬ç©ãå«ã補å€ã¯ããã®ã¬ã€ã
ã³ã¹ã«ããã BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®æ€èšããé€å€ããããå»ççšé åå€ã¯ã補å€
ã«å«ãŸããå šãŠã®åè¬ãæ¬ã¬ã€ãã³ã¹ã®ç¬¬ 2é åã³ç¬¬ 3é ã«å®ããããåºæºãæºããå Žåã«ã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã
2. åè¬ã®çç©è¬å€åŠåé¡
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã¯ãåè¬ãé«æº¶è§£æ§ããã€é«èééæ§ïŒBCS ã¯ã©ã¹ IïŒåã¯äœ
èééæ§ïŒBCS ã¯ã©ã¹ IIIïŒã®è£œå€ã«é©çšãããã
ãã€ãªãŠã§ãŒããŒã¯ãè©Šéšè£œå€ãšæšæºè£œå€äžã®åè¬ãåäžã§ãããšå®çŸ©ãããå Žåã«é©çšã
ããããã€ãªãŠã§ãŒããŒã¯ãè©Šéšè£œå€åã³æšæºè£œå€ãç°ãªãå¡©ãå«ã¿ããããã BCS ã¯ã©ã¹
IïŒé«æº¶è§£æ§ãã€é«èééæ§ïŒã«å±ããå Žåã«ãé©çšãèæ ®ãããããè©Šéšè£œå€äžã®åè¬ãã
æšæºè£œå€äžã®åè¬ãšã¯ç°ãªããšã¹ãã«ããšãŒãã«ãç°æ§äœãç°æ§äœæ··åç©ãè€åäœåã¯èªå°
äœã§ããå Žåããããã®éã㯠BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®æŠå¿µã§çšããããå®éšçæ
æ³ã§ã¯æšå®ããããšãã§ãããç°ãªããã€ãªã¢ãã€ã©ããªãã£ãããããå¯èœæ§ãããããã
ãã€ãªãŠã§ãŒããŒã¯é©çšãããªãããããã©ãã°ã¯ããããã©ãã°ãšããŠåžåãããå Žåã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®æ€èšå¯Ÿè±¡ãšããããã
2.1. 溶解æ§
åè¬ã¯ã1 åæ倧çšéã 37±1°C ã«ãã㊠1.2ïœ6.8 ã® pH ç¯å²ã§ 250 mL 以äžã®æ°Žæ§æº¶åªã«å®
å šã«æº¶è§£ããå Žåãé«æº¶è§£æ§ã«åé¡ãããã1 åæ倧çšéã§ã¯ãã®åºæºãæºãããªãããæšæº
補å€ã®æé«å«éã§ã¯äžèšã®æ¡ä»¶ã§æº¶è§£ããå ŽåãBCS ã«åºã¥ããã€ãªãŠã§ãŒããŒãæ£åœåã
ãããã«è¿œå ã®ããŒã¿ãæåºããå¿ èŠãããã
ç³è«è ã¯ã37±1 ºC ã«ãã㊠1.2ïœ6.8 ã® pH ç¯å²ã«ãããåè¬ã®æº¶è§£åºŠãå®éšçã«ç¢ºèªãã
ããšãæåŸ ããããpH 1.2ã4.5 åã³ 6.8 ã®ç·©è¡æ¶²ãå«ããå°ãªããšã 3 ã€ã® pH ã§è©äŸ¡ããå¿
èŠããããå ããŠãåè¬ã®æå°æº¶è§£åºŠã瀺ã pH ãäžèšã® pH ç¯å²å ã«ããã°ãåœè©² pH ã«ã
ãã溶解床ãè©äŸ¡ããå¿ èŠãããããããã®å®éšã§ã¯ãè¬ç©åžåãæ³å®ãããäžå®æé以äžã
溶解床ãç¶æãããããšã瀺ãå¿ èŠãããã
溶解æ§ã¯åè¬ã®ç¹æ§ã«å¿ããŠé©åãªææ³ã«ããè©äŸ¡ããå¿ èŠãããã
平衡溶解床ãè©äŸ¡ããå®éšã¯ããã©ã¹ã³æ¯ãšãæ³åã¯åŠ¥åœæ§ã瀺ãããå¥ã®æ¹æ³ãçšããŠå®
æœããã溶解床枬å®ã«é©åãªå®éšæ©åšãçšããã°ãå°éã®æ¶²éã§æº¶è§£åºŠãè©äŸ¡ããããšãã§
ããã溶解床ã®æž¬å®ãèŠå®ããã pH æ¡ä»¶äžã§å®æœãããããšã確èªããããã«ãåè©Šéšæ¶²ã«
ã€ããŠãåè¬æ·»å åŸåã³å¹³è¡¡æº¶è§£åºŠæž¬å®çµäºæã« pH ã確èªããå¿ èŠããããpH ã¯å¿ èŠã«å¿
ããŠèª¿æŽããããšãå®éšã¯å¹³è¡¡ç¶æ ã«éããŠãããšèããããé©åãªæéãèšå®ããŠè©äŸ¡ã
ãå¿ èŠãããã
ãŸãã溶解床ã®æž¬å®ã¯ã1 åæ倧çšéã®åè¬ã 250 mL ã®ç·©è¡æ¶²éã§è©äŸ¡ãããåã¯åè¬ã®é
åã³æº¶è§£æ¶²éãæ¯äŸçã«æžããææ³ã§è©äŸ¡ããããšã§ãããã
1.2ïœ6.8 ã® pH ç¯å²ã«ããã溶解床ã®æå°å€ãåè¬ã®åé¡ã«äœ¿çšãããã
溶解床ãå®èšŒããéã«ã¯ãé©åãªå ¬å®æžã«èšèŒãããŠãã溶åªãçšããŠãé©åã«ããªããŒã
ãããè©Šéšæ¹æ³ã«ãããå溶解床æ¡ä»¶/pH ã§æäœ 3 åç¹°ãè¿ã枬å®ããå¿ èŠãããã
å ããŠã溶åªäžã§åè¬ãååã«å®å®ã§ããããšãå®èšŒããå¿ èŠããããåè¬ã溶解床è©äŸ¡ã«
ãã㊠10%ãè¶ ããŠå解ããå®å®ã§ãªãå Žåã溶解床ã¯é©åã«æ±ºå®ã§ããããã®ãããåè¬
ãåé¡ããããšã¯ã§ããªããå®éšããŒã¿ã«å ããŠãæç®ããŒã¿ã溶解床決å®ã®å®èšŒã»è£ä»ã
ãšããŠäœ¿çšã§ããããšãããããæ»èªãããæç®ã§ãã£ãŠããçµæã®è³ªãååã§ããããå€
æããããã«å¿ èŠãªè©Šéšã®è©³çŽ°æ å ±ãå«ãŸããŠããªãå¯èœæ§ãããããšã«çæããããšã
2.2. èééæ§
èééæ§ã®è©äŸ¡ã¯ãããè¬ç©åæ è©Šéšã«ãããåžåéãäŸãã°çµ¶å¯Ÿçãã€ãªã¢ãã€ã©ããªã
ã£åã¯ãã¹ãã©ã³ã¹ã«åºã¥ãæ¹æ³ãåªå ãããã
絶察çãã€ãªã¢ãã€ã©ããªãã£ã 85%以äžã®å Žåãé«èééæ§ãšçµè«ä»ããããšãã§ããã
å°¿äžã«ååãããæªå€åäœïŒèŠªè¬ç©ïŒãåã¯èŠªè¬ç©ã第 1 çžé žå代è¬ç©åã³ç¬¬ 2 çžæ±å代è¬ç©
ã®åèšãæäžéã® 85%以äžã®å Žåããé«èééæ§ãšçµè«ä»ããããšãã§ãããç³äŸ¿äžã®ä»£è¬
ç©ã¯ãé žå代è¬ç©åã³æ±å代è¬ç©ã®ã¿èæ ®ããããšãã§ãããéå åã¯å æ°Žå解ã«ãã£ãŠç
ãã代è¬ç©ã¯ãåžååã«çæããããã®ã§ã¯ãªãããšãäŸãã°ãæ¶å管ã«ãããŠåŸ®çç©ã®äœ
çšã«ãã£ãŠç£çããããã®ã§ã¯ãªãããšãå®èšŒãããªãéãå«ããŠã¯ãªããªããç³äŸ¿äžã®æª
å€åäœã¯ãåžåãããè¬ç©ã®èæ±ææ³ãè žåæ³ãåã¯äžå®å®ãªä»£è¬ç©ïŒäŸãã°ãã°ã«ã¯ãã³é ž
æ±åäœãç¡«é žæ±åäœãN-é žåç©ïŒã埮çç©ã®äœçšã«ãã£ãŠæªå€åäœã«å€æããããã®ã«ç±æ¥
ããããšãé©åãªããŒã¿ã«ãã£ãŠè£ä»ããããªãéããåžåéã«å«ããããšã¯ã§ããªãã
å ¬è¡šæç®ã«åºã¥ããã in vivo ããŒã¿ïŒäŸãã°ã補åã«é¢ããæ å ±åã³å ¬è¡šãããŠãããã€ãª
ã¢ãã€ã©ããªãã£è©ŠéšïŒã¯åãå ¥ããããããšãããããæ»èªãããæç®ã§ãã£ãŠããçµæ
ã®è³ªãååã§ããããå€æããããã«å¿ èŠãªè©Šéšã®è©³çŽ°æ å ±ãå«ãŸããŠããªãå¯èœæ§ããã
ããšã«çæããã
èééæ§ã¯ãCaco-2 现èãçšããããªããŒãã»æšæºåããã in vitro è©Šéšæ³ïŒå¥æ·» I åç §ïŒã«
ãã£ãŠè©äŸ¡ããããšãã§ãããCaco-2 现èãçšããèééæ§è©Šéšã®çµæã¯ãå©çšå¯èœãªãã
è¬ç©åæ ããŒã¿ãšåãããŠè°è«ããå¿ èŠããããé«èééæ§ã in vitro 现èç³»ã«ãã£ãŠæšæž¬ã
ããå Žåã¯ãå¥æ·» Iãè©Šéšã«ãããçæäºé ãã«ç€ºãããã«èééæ§ãèœå茞éã«äŸåããªã
ããšã蚌æããå¿ èŠãããã
é«èééæ§ãå®èšŒãããªãå Žåãåè¬ã¯ BCS ã®ã¯ã©ã¹åé¡äžãäœèééæ§ãšã¿ãªãããã
æ¶å管ã§ã®å®å®æ§
é«èééæ§ãå®èšŒããããã«ãã¹ãã©ã³ã¹è©Šéšã䜿çšããå Žåãæäžéã® 85%以äžãå°¿äžã«
æªå€åäœãšããŠååãããªãéããåè¬ã®æ¶å管ã§ã®å®å®æ§ã«é¢ããè¿œå ã®ããŒã¿ãæ瀺ã
ãå¿ èŠããããæ¶å管ã§ã®å®å®æ§ã®ããŒã¿ã¯ãCaco-2 现èãçšããŠåè¬ã®é«èééæ§ã瀺ã
å Žåã«ãå¿ èŠãšãªããæ¶å管ã§ã®å®å®æ§ã¯ãå ¬å®æžã«èšèŒã®æº¶åªãåã¯æ¬äŒŒè液åã³æ¬äŒŒè ž
液ãçšããŠèšŒæããããšãã§ããããã®ä»é©åã§æ£åœãªæ¹æ³ã䜿çšããããšãã§ããããã
ãã®è©Šéšæ¶²ãš in vivo ã«ãããŠè液åã³è žæ¶²ã«è¬ç©ããããããå žåçãªæéãããªãã¡ãè
液㧠1 æéãè žæ¶²ã§ 3 æéã37âã§è¬ç©æº¶æ¶²ãã€ã³ãã¥ããŒã·ã§ã³ããããã®åŸãé©åã«ã
ãªããŒããããè©Šéšæ¹æ³ã«ããè¬ç©æ¿åºŠãå®éãããè¬ç©ã®èããå解ïŒ10%è¶ ïŒãçããå Ž
åãBCS åé¡äžã®é«èééæ§ãšå€å®ããããšã¯ã§ããªãã
3. 補å€ã® BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒãžã®èŠä»¶
補å€ã¯ãåè¬ã溶解æ§ãšèééæ§ã«é¢ããåºæºãæºããïŒBCS ã¯ã©ã¹ I åã³ IIIïŒã補å€ãå šèº«
äœçšãæããå³æŸæ§çµå£è£œå€ã§ãæšæºè£œå€ãšåäžå€åœ¢ãã€åäžå«éã§ããå Žåã«éããBCS
ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã1 åæ倧çšéã§ã¯é«æº¶è§£æ§ã®åºæºãæºãããªããã
æšæºè£œå€ã®æé«å«éã§ã¯èŠæ±ãããæ¡ä»¶ïŒç¬¬ 2.1 é åç §ïŒã§é«æº¶è§£æ§ã§ããå Žåã1 åæ倧çš
éãå«ãçšéç¯å²ã§ã®è¬ç©åæ ïŒããªãã¡ AUC åã³ CmaxïŒã®çšéæ¯äŸæ§ã瀺ãããšã§ BCS
ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å€æãã§ããããšãããã
å£è åã¯èäžåžåããã補å€ã¯ãBCS ã«åºã¥ããã€ãªãŠã§ãŒããŒé©çšã®å¯Ÿè±¡ãšã¯ãªããªãã
ããã«ãBCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã¯æ°Žã§æçšããå Žåã«ã®ã¿é©çšã§ãããæ°Žãªãã§ã®
æçšãå¯èœã§ãã補å€ã®å ŽåïŒäŸãã°ãå£è å 厩å£é ïŒãæ°Žãªãã®æ¡ä»¶äžã§ããçç©åŠçåç
æ§è©Šéšã®å®æœãå¿ èŠã§ããã
補å€ã BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã«ã¯ã補å€åŠæ¹ïŒæ·»å å€ïŒåã³è£œå€ã® in
vitro 溶åºæ§ã«é¢ããåºæºãæºããå¿ èŠãããã補å€ã®åå ¥ãåºæºã¯ã以äžã®ç¬¬ 3.1 é åã³ç¬¬
3.2 é ã«èšèŒãããŠããã
3.1. æ·»å å€
è©Šéšè£œå€ã®åŠæ¹ã¯æšæºè£œå€ãæš¡å£ããããšãçæ³çã§ããããããã補å€éã§æ·»å å€ã®éã
ãçããå Žåããã®éããæ¶å管ã«ãããè¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã«ã€ããŠè©äŸ¡ãã
å¿ èŠãããããã®è©äŸ¡ã«ã¯ãæ·»å å€ã®åœ±é¿ã ãã§ãªãåè¬ã®æ§è³ªãèæ ®ããå¿ èŠããããBCS
ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã«ã¯ãç³è«è ã¯ãæ·»å å€ã®éããåè¬ã®åžåããã
ã¡ã€ã«ãããªãã¡åžåé床åã³éã«åœ±é¿ããªãããšã®æ£åœãªçç±ããã¡ã«ããºã åã³ãªã¹ã¯
ã«åºã¥ãã¢ãããŒããçšããŠç€ºããªããã°ãªããªãããã®ãããªè©äŸ¡ãå®æœããããã®ãã
ãŒãã£ãŒããå¥æ·» II ã®å³ 1 åã³å³ 2 ã«ç€ºãã
æ·»å å€ãåè¬ã®æº¶è§£æ§ãæ¶å管éåãééæéåã³ãã©ã³ã¹ããŒã¿ãŒã«ããæ©æ§ãå«ãè žç®¡
èééæ§çã®æ¶å管ã«ãããè¬ç©åžåãŸã§ã®éçšã«åãŒãåŸã圱é¿ãèæ ®ããå¿ èŠãããã
è¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã«ã¯ãç³ã¢ã«ã³ãŒã«é¡ïŒäŸãã°ããã³ãããŒã«ã
ãœã«ãããŒã«ïŒåã¯çé¢æŽ»æ§å€ïŒäŸãã°ãã©ãŠãªã«ç¡«é žãããªãŠã ïŒãªã©ããããæ·»å å€ãè¬
ç©åžåã«åœ±é¿ãåãŒããªã¹ã¯ã¯ã以äžã®ç¹ãèæ ®ããã¡ã«ããºã ã«åºã¥ããŠè©äŸ¡ããå¿ èŠã
ããã
䜿çšãããæ·»å å€ã®é
æ·»å å€ãåžåã«åœ±é¿ãåãŒãå¯èœæ§ããããšèããããã¡ã«ããºã
åè¬ã®åžåç¹æ§ïŒåžåã®é床ãéåã³æ©æ§ïŒ
è©Šéšè£œå€åã³æšæºè£œå€äžã®è¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã®éã¯ãæ·»å å€ã®å€
æŽãæå°éã«æããããããã«ã補åéçºäžã«æ€èšããå¿ èŠããããé å€ã®ã³ãŒãã£ã³ã°ã«
å«ãŸããå°éã®æ·»å å€ãåã¯åœè©²åè¬ã«ã€ããŠèšèŒãããéŸå€æªæºã®éã®æ·»å å€ã¯ãããŸã
æžå¿µãšã¯ãªããªãã
å®çŸ©äžãBCS ã¯ã©ã¹ I ã®åè¬ã¯ããåžåããããŸããã®åžåã¯æº¶è§£æ§ã«ãèééæ§ã«ãå¶é
ãããªãããããã£ãŠãBCS ã¯ã©ã¹ I ã®åè¬ã¯äžè¬ã«ä»ã® BCS ã¯ã©ã¹ã®åè¬ãšæ¯ã¹ãŠãæ·»å
å€ãè¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®äœãååç©çŸ€ã§ãããBCS ã¯ã©ã¹ I ã®åè¬ãå«ã補å€
ã«å¯Ÿããæ·»å å€ã®åœ±é¿ã®æ€èšã¯ãè¬ç©åžåã®é床åã¯éãå€åããå¯èœæ§ã«çŠç¹ãåœãŠãå¿
èŠããããäŸãã°ãè¬ç©ãèœååã蟌ã¿ã«ããé«èééæ§ã瀺ãããšãç¥ãããŠããå Žåã
åã蟌ã¿ãã©ã³ã¹ããŒã¿ãŒãé»å®³ããæ·»å å€ã¯ãæžå¿µãšãªãå¯èœæ§ãé«ããåžåé床ãé ã
BCS ã¯ã©ã¹ I ã®åè¬ã«ã€ããŠã¯ãæ·»å å€ãåžåé床ãå¢å ãããå¯èœæ§ãèæ ®ããå¿ èŠãã
ãã
BCS ã¯ã©ã¹ I ã®åè¬ã«ã€ããŠã¯ãåžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ãé€ããæ·»å å€ã®
çš®é¡ãéã®éãã¯èš±å®¹ããããè¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã«ã€ããŠã¯ãçš®
é¡ã¯åãã§éã¯é¡äŒŒãããªãã¡æšæºè£œå€ã«å«ãŸããåœè©²æ·»å å€ã®éã®Â±10%以å ã§ãªããã°
ãªããªããããã«ãè¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã 2 皮以äžå«ãå Žåãåœè©²
æ·»å å€ã®å·®ã®çµ¶å¯Ÿå€ã®åã¯Â±10%以å ã§ãªããã°ãªããªãã
BCS ã¯ã©ã¹ III ã®åè¬ã¯ãæ·»å å€ã®åœ±é¿ãããåãããããšèããããŠããããããã®åè¬ã¯
èééæ§ãäœããéšäœç¹ç°çãªè¬ç©åžåæ§ã瀺ãå¯èœæ§ããããããæ·»å å€ãåžåã«åœ±é¿ã
äžãåŸãæ©æ§ã BCS ã¯ã©ã¹ I ã®åè¬ãããå€ããBCS ã¯ã©ã¹ III ã®åè¬ã«ã€ããŠã¯ãå šãŠã®
æ·»å å€ã®çš®é¡ã¯åãã§éã¯é¡äŒŒããŠããªããã°ãªããªãïŒãã ãããã£ã«ã ã³ãŒããã«ãã»
ã«ã®æ®»ã®æ·»å å€ã¯é€ãïŒãè¬ç©åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã«ã€ããŠã¯ãçš®é¡ã¯å
ãã§éã¯é¡äŒŒãããªãã¡æšæºè£œå€ã«å«ãŸããåœè©²æ·»å å€ã®éã®Â±10%以å ã§ããã€è¬ç©åžåã«
圱é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ã 2 皮以äžå«ãå Žåãåœè©²æ·»å å€ã®å«æçã®å·®ã®çµ¶å¯Ÿå€ã®
ç·åã¯Â±10%以å ã§ãªããã°ãªããªãããããè¡š 1 ã«ç€ºãã蚱容ãããæ·»å å€ã®éãã®äŸãã
å¥æ·» II ã«ç€ºããçè²å€åã³éŠæã補å€äžã«åŸ®éã«å«ãŸããå Žåããã®å«æçã®éãã¯èæ ®ã
ãªããšãããããšãããã
è¡š 1 ãé©çšããéã®æ³šæç¹ãšããŠãæšæºè£œå€ã«ããããã£ã«ã ã³ãŒãå±€ã®ééã決å®ããã
ãšãå°é£ã§ããããšãæãããããè¡š 1 ã¯ç³è«è ã®ç®æšå€ãšããŠæäŸããŠããããã®è¡šãã
éžè±ããå Žåãäžèšã®ååã«åºã¥ããŠé©åãªèª¬æãå¿ èŠã«ãªãã
è¡š 1ïŒBCS ã¯ã©ã¹ III ã®åè¬ãå«ã補å€ã«ãããŠèš±å®¹ãããæ·»å å€ã®éãïŒç®æšå€ïŒ
éãé¡äŒŒã§ãããšã¯ãBCS ã¯ã©ã¹ III ã®åè¬ãå«ã補å€ã«ãããæ·»å å€ã®éããã以äž
ã®ç®æšå€ãè¶ ããªãããšã瀺ã
æ·»å å€ã®åé¡ æšæºè£œå€äžã®æ·»å å€è³ªéã«å¯Ÿããå²å
åžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€
1 ã€ã®æ·»å å€ã«ã€ãïŒ
å«æçã®å·®ã®çµ¶å¯Ÿå€ã®ç·åïŒ
10%
10%
å æ žééã«å¯Ÿããå«æç(w/w)ã®çµ¶å¯Ÿå€ã®å·®
å šãŠã®æ·»å å€:
è³Šåœ¢å€ 10%
厩å£å€
ã§ãã·ã 6%
ãã®ä» 2%
çµåå€ 1%
æ»æ²¢å€
ã¹ãã¢ãªã³é žå¡© 0.5%
ãã®ä» 2%
æµååå€
ã¿ã«ã¯ 2%
ãã®ä» 0.2%
蚱容ã§ããå šãŠã®æ·»å å€ã®å·®ã®åèš%
ïŒåžåã«åœ±é¿ãåãŒãå¯èœæ§ã®ããæ·»å å€ãå«ãïŒ: 10%
泚ïŒå æ žã«ã¯é å€ã®ãã£ã«ã ã³ãŒããã«ãã»ã«ã®æ®»ã¯å«ãŸãªãã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã¯åäžå€åœ¢ãã€åäžå«éã§ããå»ççšé åå€ã«é©çšãããã
BCS ã¯ã©ã¹ I ã®åè¬ã®ã¿ãå«æããå»ççšé åå€ã§ã¯ãæ·»å å€ã«é¢ããåºæºã¯ BCS ã¯ã©ã¹ I
ã®åè¬ã®åºæºã«åŸãããšãBCS ã¯ã©ã¹ III ã®åè¬ã®ã¿ãå㯠BCS ã¯ã©ã¹ I ã®åè¬ãš BCS ã¯ã©
ã¹ III ã®åè¬ãå«ãå»ççšé åå€ã§ã¯ãæ·»å å€ã«é¢ããåºæºã¯ BCS ã¯ã©ã¹ III ã®åè¬ã®åºæºã«
åŸãããšã
3.2. In vitro 溶åºè©Šéš
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒãé©çšããå Žåã® in vitro 溶åºè©Šéšã¯ãå®çç£ã®å·¥çšã§è£œé ã
ãã代衚çãªïŒãããã®è©Šéšè£œå€ãš 1 ãããã®æšæºè£œå€ãçšããŠå®æœããå¿ èŠããããè©Šéš
補å€ã¯ãå¥ã«åŠ¥åœæ§ã瀺ãããªãéããå®çç£ãããã®å°ãªããšã 1/10 ã®å€§ããå㯠10 äž
åäœã®ãã¡ããããã倧ãããããã®ãã®ãšããå¿ èŠããããïŒèšåºïŒéçºæ®µéã§ã¯ãæ£åœãª
çç±ãããã°ããå°ããªãµã€ãºã®ãããã蚱容ãããããšããããIn vitro 溶åºè©Šéšã§ã¯ãå ¬
å®æžã«èŠå®ãããè£ çœ®ãçšããé©åã«ããªããŒããããåææ¹æ³ãçšããå¿ èŠãããã
溶åºè©Šéšã¯ä»¥äžã®æ¡ä»¶ã«åŸã£ãŠå®æœãã補å€ã®æº¶åºãããã¡ã€ã«ãæããã«ããããšïŒ
è£ çœ®ïŒããã«æ³åã¯å転ãã¹ã±ããæ³
è©Šéšæ¶²ã®éïŒ900 mL 以äžïŒå質管çïŒQCïŒè©Šéšã§éžæãããè©Šéšæ¶²éãæšå¥šïŒ
è©Šéšæ¶²ã®æž©åºŠïŒ37±1°C
å転é床ïŒããã«æ³â50 rpm
å転ãã¹ã±ããæ³â100 rpm
æšæºè£œå€åã³è©Šéšè£œå€ã®ããããå°ãªããšã 12 ããã»ã«ä»¥äžã®æº¶åºè©ŠéšããŒã¿ã«åº
ã¥ã溶åºãããã¡ã€ã«ã®è©äŸ¡ãè¡ãããšã
3 çš®é¡ã®ç·©è¡æ¶²ïŒpH 1.2ãpH 4.5 åã³ pH 6.8ãè¬å±æ¹ã«èšèŒã®ç·©è¡æ¶²ã䜿çšããããšã
æå°ã®æº¶è§£åºŠã瀺ã pH ã®ç·©è¡æ¶²ïŒäžèšã®ç·©è¡æ¶²ãšç°ãªãå ŽåïŒã«ããè¿œå ã®è©Šéšã
æ±ããããããšãããã
ææ©æº¶åªã®äœ¿çšã¯èªããããªãããŸããçé¢æŽ»æ§å€ã¯æ·»å ããªãããšã
In situ æ€åºæ³ãçšããå Žåãé€ããè©Šæ溶液ã¯ãéãè¡ãªããæ¡åããããšã
æ¶æ©ãèµ·ããããšãå®èšŒãããŠãããŒã©ãã³ã«ãã»ã«åã¯ãŒã©ãã³ã³ãŒãã£ã³ã°ã
æããé å€ã«ã€ããŠã¯ãé©åã«æ£åœåãããã°é µçŽ ã®äœ¿çšãèªããããã
ããã«æ³ 50 rpm ã«ãããŠãè©Šéšè£œå€åã³æšæºè£œå€ã®åæ¹ã§æº¶åºçã®ã°ãã€ãã倧ããåã¯å
ç©ç©ãèªããããå Žåã¯ãå転ãã¹ã±ããæ³ 100 rpm ã䜿çšããããšãæšå¥šãããããŸãã
æ£åœãªçç±ãããã°ãå ç©ç©ã®åé¡ã解決ããããã代æ¿æ³ïŒäŸãã°ãã·ã³ã«ãŒã®äœ¿çšã劥
åœãšå€æãããä»ã®ææ³ïŒã®å©çšãèæ ®ãããããå®æœããå šãŠã®è©Šéšçµæã¯æåºããå¿ èŠ
ãããã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã«ã¯ãBCS ã¯ã©ã¹ I ã®åè¬ãå«ã補å€ã§ã¯ãå š
ãŠã®èŠå®ãããæ¡ä»¶äžã«ãããŠãè©Šéšè£œå€ãšæšæºè£œå€ã®äž¡æ¹ã§éåžžã«éã溶åºæ§ã瀺ãïŒ15
å以äžã§å¹³å 85%以äžã®æº¶åºïŒãåã¯éã溶åºæ§ã瀺ãïŒ30 å以äžã§å¹³å 85%以äžã®æº¶åºïŒã
ã〠in vitro 溶åºç¹æ§ã®é¡äŒŒæ§ïŒããªãã¡ f2é¢æ°ã§ã®æ¯èŒïŒã瀺ãå¿ èŠããããäž¡æ¹ã®è£œå€ã
éåžžã«éã溶åºã瀺ãå Žåãé€ãã以äžã«ç€ºãæ¹æ³ã§æº¶åºãããã¡ã€ã«ãé¡äŒŒã§ããããšã
瀺ããªããã°ãªããªãã
溶åºãããã¡ã€ã«ãæ¯èŒããå Žåã以äžã®åŒãçšã㊠f2é¢æ°ãæ±ããïŒ
f2 = 50 ⢠log {[1 + (1/n)Σt=1n (Rt - Tt)2]-0.5 ⢠100}
ãã®åŒã«ãããŠãf2 ã¯é¡äŒŒæ§ä¿æ°ãn ã¯æç¹æ°ãR(t)ã¯è©Šéšéå§åŸã®æé t ã«ãããæšæºè£œå€
ã®å¹³å溶åºçïŒT(t)ã¯è©Šéšéå§åŸã®æé t ã«ãããè©Šéšè£œå€ã®å¹³å溶åºçã§ããã
f2é¢æ°ã¯ã以äžã®æ¡ä»¶ã«åºã¥ãèšç®ããïŒ
æäœ 3 æç¹ïŒãŒãã¯é€ãïŒ
2 補å€ã§åãæç¹ã䜿çšããããšã
å補å€ã«ã€ãåæç¹ã®å€ã®å¹³åå€ã
ããããã®è£œå€ã®å¹³å溶åºçã 85%以äžãšãªãæåã®æç¹ãŸã§ã
å¹³å溶åºçã®ããŒã¿ã®äœ¿çšãå¯èœã«ããã«ã¯ãå€åä¿æ°ã¯åæã®æç¹ïŒ10 åãŸã§ïŒã§
㯠20%ããä»ã®æç¹ã§ã¯ 10%ãè¶ ããŠã¯ãªããªãã
f2é¢æ°ã 50 以äžã®å Žåã2 ã€ã®æº¶åºãããã¡ã€ã«ã¯é¡äŒŒããŠãããšå€å®ããããè©Šéšè£œå€ãš
æšæºè£œå€ã®äž¡æ¹ã«ã€ããŠè¬ç©ã®è¡šç€ºéã® 85%以äžã 15 åã§æº¶åºããå Žåãf2é¢æ°ã«ããæ¯èŒ
ã¯å¿ èŠãªãã溶åºãããã¡ã€ã«ã¯é¡äŒŒããŠãããšå€å®ããããå€åä¿æ°ã倧ãããäžèšæ¡ä»¶
ãæºãããªãå Žåã¯ãf2ã®èšç®ã¯äžæ£ç¢ºã§ãããšèãããã溶åºã®é¡äŒŒæ§ãçµè«ä»ããããšã¯
ã§ããªãã
BCS ã«åºã¥ããã€ãªãŠã§ãŒããŒã®å¯Ÿè±¡ãšãªãã«ã¯ãBCS ã¯ã©ã¹ III ã®åè¬ã§ã¯ãèŠå®ããã
æ¡ä»¶äžã«ãããŠãè©Šéšè£œå€ãæšæºè£œå€ã®äž¡æ¹ãéåžžã«éãïŒ15 å以äžã§å¹³å溶åºç 85%以äž
ã®æº¶åºïŒin vitro 溶åºç¹æ§ã瀺ãå¿ èŠãããã
å»ççšé åå€ã«ãããŠã溶åºãããã¡ã€ã«ã¯ãå»ççšé åå€äžã®å šãŠã®åè¬ãåºæºãæºãã
å¿ èŠããããBCS ã¯ã©ã¹ Iã®åè¬ã®ã¿ãå«æããå»ççšé åå€ã§ã¯ã溶åºã«é¢ããåºæºã¯ BCS
ã¯ã©ã¹ I ã®åè¬ã®åºæºã«åŸãããšãBCS ã¯ã©ã¹ III ã®åè¬ã®ã¿ãå«æããå»ççšé åå€ã§ã¯ã
溶åºã«é¢ããåºæºã¯ BCS ã¯ã©ã¹ III ã®åè¬ã®åºæºã«åŸãããšãBCS ã¯ã©ã¹ I åã³ BCS ã¯ã©ã¹
III ã®åè¬ã®äž¡æ¹ãå«ãå»ççšé åå€ã§ã¯ãæåããšã«è©²åœãã BCS ã¯ã©ã¹ã®æº¶åºåºæºãé©
çšããããšã
2 ã€ä»¥äžã®å«éãæãã補å€ã§ã¯ãBCS ã¢ãããŒãã¯å«éããšé©çšããå¿ èŠããããããªã
ã¡ãããããã®å«éã®è©Šéšè£œå€ãšæšæºè£œå€ã®æº¶åºãããã¡ã€ã«ãæ¯èŒããããšãæ±ããããã
4. ææžå
ç³è«è ã¯ãè©Šéšè£œå€ã«é¢ããè©Šéšåè¬ãšè£œå€ã®éèŠå質ç¹æ§ã«é¢ããå®å šãªæ å ±ãšæšæºè£œå€
ã«é¢ããã§ããéãå€ãã®æ å ±ãæäŸããå¿ èŠããããæ å ±ã«ã¯ä»¥äžãå«ããããããã«é
å®ãããªãïŒçµæ¶å€åœ¢åã³é¡åç°æ§äœã®çŽåºŠïŒåè¬åã¯è£œå€ã®ãã€ãªã¢ãã€ã©ããªãã£è¥ã
ãã¯çç©åŠçåçæ§ã®åé¡ã«é¢ããããããæ å ±ãããã«ã¯æç®èª¿æ»åã³ç³è«è ã«ããç 究
ãå«ããå šãŠã®è©Šéšãããã³ã«åã³å ±åæžãæåºããå¿ èŠããããããªããŒããããè©Šéšæ³
ã«é¢ããæ å ±ã«ã€ããŠææ°ã®èŠå¶ã¬ã€ãã³ã¹ãšæ¹éã«åŸã£ãŠé©åã«è©³è¿°ããå¿ èŠãããã
å ±åæžã®æ§åŒã«ã¯ãåã åã³å¹³åå€ã®çµæãšèŠçŽçµ±èšéã瀺ãè¡šåã³å³ãå«ããå¿ èŠãããã
å ±åæžã«ã¯ãå šãŠã®æ·»å å€ã«ã€ããŠãè©Šéšè£œå€ãšæšæºè£œå€ã®æ·»å å€ã®çš®é¡ãåã³å¿ èŠã«å¿ã
ãŠéã®éãã®æ å ±ãå«ããå¿ èŠãããã
䜿çšãããåææ¹æ³ã«ã€ããŠã¯ãããªããŒã·ã§ã³ãåæèœãã©ã¡ãŒã¿ã®åŠ¥åœæ§ãå«ããå šãŠ
èšè¿°ããå¿ èŠããããè©Šéšè£œå€åã³æšæºè£œå€ã®ãããã®æ å ±[åäœçšéïŒå«éåã³å®éå€ïŒã
ãããçªå·ãææ¡ããŠããã°è£œé æ¥ãšããããµã€ãºãåã³äœ¿çšæé]ãå«ããå šãŠã®è©Šéšæ¹æ³
åã³è©Šéšæ¶²ã®è©³çŽ°ãªèšè¿°ãå¿ èŠã§ããã溶åºè©Šéšã®å ±åæžã¯ãè£ çœ®ãè±æ°ãè©Šææ¡åæã®ã
éæ¹æ³ãæ¡åéçã溶åºè©Šéšæ¡ä»¶ã«é¢ããæ å ±ãå«ãå®éšæ¡ä»¶ãšåææ¹æ³ãå šãŠèšèŒããå¿
èŠãããã
ãŸããCaco-2 现èãçšããèééæ§è©Šéšãå®æœããå Žåã¯ãé©çšãããæ¹æ³ã®å šãŠã®æ å ±ã
èšèŒããå¿ èŠãããïŒå¥æ·» I åç §ïŒã
5. çšèªé
AUCïŒè¡äžæ¿åºŠïŒæéæ²ç·äžé¢ç©
BCSïŒBiopharmaceutics Classification System
CmaxïŒæé«è¡äžæ¿åºŠ
FDCïŒFixed-dose combination
QCïŒQuality control
rpmïŒ1 ååœããã®å転æ°
å¥æ·» IïŒCaco-2现èãçšããèééæ§è©Šéšã«ãããçæäºé
ããçµè žè ºçç±æ¥ã®çŽ°èæ ªãå¹é€ãã Caco-2 äžç®çŽ°èåå±€èãçšããèééæ§è©Šéšã¯ããã
ã«ãããè¬ç©ã®æ¶å管åžåã®æšå®ã«åºã䜿çšãããŠãããCaco-2 现èã¯ãèªçºçã圢æ åŠç
åã³çååŠçãªè žçŽ°èã®ååãåããå°è žã«èŠããããããªé 端ã®å·åçžã现èéã¿ã€ããž
ã£ã³ã¯ã·ã§ã³ãåã³èœåãã©ã³ã¹ããŒã¿ãŒãšãã£ã现è極æ§ãæããŠãããæåºïŒäŸãã° P-
gpãBCRPãMRP2ïŒåã³åã蟌ã¿ïŒäŸãã° PepT1ãOATP2B1ãMCT1ïŒãã©ã³ã¹ããŒã¿ãŒã®çº
çŸãäœããåã¯çºçŸããŠããªãå¯èœæ§ããããããBCS ã®åé¡ã«ãããŠé«èééæ§ã§ããã
ãšãè£ä»ããããã®ããŒã¿ãšã㊠Caco-2 现èã«ããè©äŸ¡ãå©çšããã«ããã£ãŠã¯ãåå茞é
ãããè¬ç©ã«éãããïŒè©Šéšã«ãããçæäºé ã®é ãåç §ïŒã
è©Šéšæ¹æ³ã®ããªããŒã·ã§ã³
BCS ã®èééæ§ã決å®ããããã® Caco-2 现èãçšããè©Šéšã®åŠ¥åœæ§ã¯ã0ãäœïŒ50%æªæº)ã
äžç床ïŒ50 â 84%ïŒãåã³é«ïŒ85%以äžïŒèééæ§ã瀺ãã¢ãã«è¬ç©ã䜿çšããŠãå®éšã«åºã¥
ãèééæ§ã®å€ãšããã«ãããè¬ç©ã®åžåéãšã®éã®é äœé¢ä¿ã確ç«ããããšã«ãã£ãŠç€ºã
å¿ èŠããããé«ãäžãäœèééæ§åã³éèééæ§ããŒã«ãŒãç¹åŸŽä»ãããããããªããŒã·ã§
ã³ã§ã¯ååãªæ°ã®ã¢ãã«è¬ç©ã䜿çšããããšãæšå¥šãããïŒé«ãäžç床åã³äœã®èééæ§ã«
ããŽãªãŒã§ããããæäœ 5 ã€åã³éèééæ§ã®ã«ããŽãªãŒã§ 1 ã€ãæšå¥šïŒäŸã¯è¡š 2 ã«ç€ºãïŒã
ãŸããä¿¡é Œã§ããè¬ç©ã®èééæ§ã«é¢ããæšå®å€ã瀺ãããã«ãååãªåæ°ã®è©Šéšãç¹°ãè¿
ãå¿ èŠãããïŒæäœ 3 åïŒã確ç«ããé¢ä¿æ§ã«ãããäœãäžç床åã³é«èééæ§ã®è¬ç©ã®åºå¥
ãå¯èœã§ããã
Caco-2 现èåå±€èã®å®å šæ§ã¯ãå®éšã®ååŸã§ã®çµäžç®é»æ°æµæïŒTEERïŒæž¬å®å€åã³/åã¯ä»
ã®é©åãªææšãæ¯èŒããããšã«ãã£ãŠç¢ºèªããå¿ èŠãããã
ãŸãã现èåå±€èã®å®å šæ§ã¯ãéèééæ§ã§ããããšãæ¢ç¥ã§ããååç©ãçšããŠå®èšŒãã
å¿ èŠãããïŒè¡š 2 åç §ïŒã
è©Šéšæ¹æ³ã®ããªããŒã·ã§ã³ã®å ±åã«ã¯ãè©Šéšæ¹æ³ã®ç¢ºç«ã®ããã«éžæããã¢ãã«è¬ç©ã«é¢ã
ãããã«ãããåžåéïŒå¹³åå€ãæšæºåå·®ãå€åä¿æ°ïŒã®ããŒã¿ãå«ããã®ãªã¹ããšãåã¢ã
ã«è¬ç©ã®èééæ§ã®å€ïŒå¹³åå€ãæšæºåå·®ãå€åä¿æ°ïŒãåã¢ãã«è¬ç©ã®èééæ§ã®ã«ããŽãª
ãŒã瀺ããšãšãã«ãé«èééæ§ã«ããŽãªãŒã®å¢çåã³è©Šéšè¬ç©ã®åé¡ã®ããã«éžæããé«è
ééæ§ã®ã¢ãã«è¬ç©ã®èééæ§ãæ瀺ãããèééæ§ã®é¢æ°ãšããŠã®åžåéã®ããããïŒå¹³
åå€Â±æšæºåå·®ãå㯠95%ä¿¡é ŒåºéïŒãå«ããå¿ èŠãããã
ãŸããè©Šéšæ¹æ³ã®èª¬æããããŒæº¶æ¶²äžã®è¬ç©æ¿åºŠãåææ¹æ³ã®èª¬æãèééæ§ã®ç®åºã«äœ¿çš
ããèšç®åŒãæ瀺ããå¿ èŠããããããã«ãæåºèœã«é¢ããæ å ±ãäŸãã°ãæ¢ç¥ã®åºè³ªã®å
æ¹å茞éããŒã¿ãæ瀺ããå¿ èŠãããã
è©Šéšã«ãããçæäºé
è©Šéšè¬ç©ãåå茞éãããããšã瀺ãå¿ èŠããããããã¯æ¢ç¥ã®æåºãã©ã³ã¹ããŒã¿ãŒãçº
çŸããŠããé©åãªè©Šéšç³»ãçšããŠãäŸãã°ã枬å®ãã in vitro èééæ§ãè¬ç©ã®åææ¿åºŠïŒäŸ
ãã°ãæé«å«éã 250 mL ã«æº¶è§£ãã 0.01ã0.1ãåã³ 1 åïŒåã¯èŒžéæ¹åã«äŸåããªãããš
ã«ãã£ãŠïŒefflux ratioãããªãã¡éžæããè¬ç©æ¿åºŠã«ãããŠãåºåºèåŽããé 端èåŽãšé 端è
åŽããåºåºèåŽã®èŠããã®èééæ§ïŒPappïŒã®æ¯ã 2 æªæºïŒç¢ºèªããããšãã§ããã
efflux ratio = Papp BL-AP/Papp AP-BL
æåºãã©ã³ã¹ããŒã¿ãŒã®æ©èœççºçŸã¯ãæåºãã©ã³ã¹ããŒã¿ãŒã®å žååºè³ªè¬ïŒäŸãã°ãdigoxinã
vinblastineãrhodamine 123ïŒã®åæ¹å茞éãäžé£œåæ¿åºŠã«ãããŠç¢ºèªããé察称æ§ã瀺ãããš
ãå¿ èŠã§ããã
èééæ§è©Šéšã§äœ¿çšããè©Šéšè¬ç©ã®æ¿åºŠã«ã€ããŠããã®åŠ¥åœæ§ã瀺ãå¿ èŠããããè¬ç©ã®è
ééæ§ã®æ±ºå®ã«äœ¿çšãããããªããŒãããã Caco-2 现èãçšããè©Šéšã§ã¯ãããªããŒã·ã§ã³
ã«ãã確ç«ãããæ¡ä»¶ãçšããè©Šéšæ³ã®äžè²«æ§ã瀺ãããã«å éšæšæºãšããŠäžç床åã³é«è
ééæ§ã®ã¢ãã«è¬ç©ã䜿çšãããããªãã¡ããããŒæº¶æ¶²äžã«è©Šéšè¬ç©ãšãšãã«å ããå¿ èŠã
ãããå éšæšæºã¯è©Šéšè¬ç©ãšã®é©åæ§ã«åºã¥ãéžæããå¿ èŠããããããªãã¡ããããã¯è
ããç©ççãååŠçåã¯èééæ§ã«é¢ããçžäºäœçšã瀺ãã¹ãã§ã¯ãªããè©Šéšè¬ç©ã®èéé
æ§è©äŸ¡ãè¡ãåãå¹é€çŽ°èã® well ã«å éšæšæºãæ·»å ããããšãé©ããªãå Žåã«ã¯ãå éšæšæº
ã®èééæ§ã¯ãåãåå±€èãçšããŠè©Šéšè¬ç©ã®è©äŸ¡ã®åŸã«è©äŸ¡ããåã¯åããã¬ãŒãã®å¥ã®
åå±€èã§è©äŸ¡ããããšãã§ãããå éšæšæºã®èééæ§ã®å€ã¯ãè©Šéšæ¹æ³ã®ããªããŒã·ã§ã³ã«
ãããŠå®æœãããè©Šéšãå«ããç°ãªãè©Šéšéã§äžè²«ããŠããå¿ èŠããããå éšæšæºåã³æåº
ãã©ã³ã¹ããŒã¿ãŒã®åºè³ªãšãªãã¢ãã«è¬ç©ã«é¢ããå€å®åºæºãèšå®ããå¿ èŠããããè©Šéšçµ
äºæã«è©Šéšè¬ç©åã³å éšæšæºã®å¹³åååçãè©äŸ¡ããå¿ èŠããããååçãïŒ80%ã®å Žåã¯ã
å局现èäžåã³å®éšåšå ·ã«æ®åããè¬ç©éãå«ããç©è³ªåæ¯ãè©äŸ¡ããããšã
BCS ã®åé¡ã®ããã®è©Šéšè¬ç©ã®èééæ§ã®è©äŸ¡ã¯ãäžç床/é«èééæ§ã«ããŽãªãŒã®å¢çã«è¿
ãèééæ§ã瀺ãé«èééæ§ã®å éšæšæºãéžæããããšã«ãã£ãŠå®¹æã«ãªãå¯èœæ§ãããã
è©Šéšè¬ç©ã¯ããã®èééæ§ã®å€ãéžæãããé«èééæ§ã®å éšæšæºã®èééæ§ã®å€ãšçãã
åã¯é«ãå Žåã«ãé«èééæ§ãšã¿ãªãããã
è©Šéšè¬ç©ã®é«èééæ§ãè£ä»ããããã®æ å ±ïŒå¹³åå€ãæšæºåå·®ãå€åä¿æ°ïŒã«ã¯ãè©Šéšè¬ç©
ã®èééæ§ããŒã¿ãå éšæšæºãæ¶å管ã«ãããå®å®æ§ã«é¢ãã in vitro ã®æ å ±åã³åå茞éã§
ããããšãè£ä»ããããŒã¿ãå«ããå¿ èŠãããã
è¡š 2ïŒèééæ§è©Šéšã®ããªããŒã·ã§ã³ã®ããã®ã¢ãã«è¬ç©ã®äŸ
ã°ã«ãŒã è¬ç©
é«èééæ§
ïŒfa â§85%ïŒ
Antipyrine
Caffeine
Ketoprofen
Naproxen
Theophylline
Metoprolol
Propranolol
Carbamazepine
Phenytoin
Disopyramide
Minoxidil
äžç床èééæ§
ïŒfa =50-84%ïŒ
Chlorpheniramine
Creatinine
Terbutaline
Hydrochlorothiazide
Enalapril
Furosemide
Metformin
Amiloride
Atenolol
Ranitidine
äœèééæ§
ïŒfa ïŒ50%ïŒ
Famotidine
Nadolol
Sulpiride
Lisinopril
Acyclovir
Foscarnet
Mannitol
Chlorothiazide
Polyethylene glycol 400
Enalaprilat
éèééæ§ FITC-Dextran
Polyethylene glycol 4000
Lucifer yellow
Inulin
ã°ã«ãŒã è¬ç©
Lactulose
æåºãã©ã³ã¹ããŒã¿ãŒã®
åºè³ª
Digoxin
Paclitaxel
Quinidine
Vinblastine
å¥æ·» IIïŒæ·»å å€ã®éãã®è©äŸ¡ã«é¢ãã詳现æ å ±
å³ 1. BCS ã¯ã©ã¹ I ã®åè¬
å³ 2. BCS ã¯ã©ã¹ III ã®åè¬
åãå ¥ããããæ·»å å€ã®éãã®äŸ
äŸ1ïŒBCSã¯ã©ã¹Iã®ãã€ãªãŠã§ãŒããŒ
è©Šéšè£œå€ã®åŠæ¹ã§äœ¿çšãããæ·»å å€ã®çš®é¡ã¯ãæšæºè£œå€ãšåãã§ããããŸãã補å€ã¯è¬ç©åž
åãžã®åœ±é¿ãç¥ãããŠããåã¯çãããŠããæ·»å å€ã§ãããœã«ãããŒã«ãå«ããè©Šéšè£œå€äž
ã®ãœã«ãããŒã«ã®éã¯ãæšæºè£œå€äžã®éã«åºã¥ããœã«ãããŒã«ã®èš±å®¹å¹ ã§ãã 45 mg ãã
55 mg ã®ç¯å²å ã«ããïŒ50 mg±10%ïŒã
æå 質éïŒmgïŒ
æšæºè£œå€
質éïŒmgïŒ
è©Šéšè£œå€
åè¬ 100 100
çµæ¶ã»ã«ããŒã¹ïŒè³Šåœ¢å€ïŒ 100 95
ãœã«ãããŒã«ïŒè³Šåœ¢å€ïŒ 50 55
HPMCïŒçµåå€ïŒ 10 10
ã¿ã«ã¯ïŒæµååå€ïŒ 5 5
åèš 265 265
äŸ2ïŒBCSã¯ã©ã¹IIIã®ãã€ãªãŠã§ãŒããŒ
è©Šéšè£œå€ã®åŠæ¹ã§äœ¿çšãããæ·»å å€ã®çš®é¡ã¯ãæšæºè£œå€ãšåãã§ããããŸãã補å€ã¯è¬ç©åž
åãžã®åœ±é¿ãç¥ãããŠããåã¯çãããŠããæ·»å å€ã§ãããœã«ãããŒã«ãå«ããè©Šéšè£œå€äž
ã®ãœã«ãããŒã«ã®éã¯ãæšæºè£œå€äžã®éã«åºã¥ããœã«ãããŒã«ã®èš±å®¹å¹ ã§ãã9 mgãã11 mg
ã®ç¯å²å ã«ããïŒ10 mg±10%ïŒããã®ä»ã®æ·»å å€ã«ã€ããŠãéã®éãã¯è¡š1ã«ç€ºããåºæºå ã§
ããã
æå
æšæºè£œå€ è©Šéšè£œå€ å æ žééã«å¯Ÿ
ããå«æçã®
絶察å€ã®å·®
質é
ïŒmgïŒ
å æ žééã«å¯Ÿ
ããå«æç
ïŒ%w/wïŒ
質é
ïŒmgïŒ
å æ žééã«å¯Ÿ
ããå«æç
ïŒ%w/wïŒ
åè¬ 100 49.3% 100 46.5% --
ä¹³ç³æ°Žåç©ïŒè³Šåœ¢å€ïŒ 85 41.9% 97 45.1% 3.2%
ãœã«ãããŒã«ïŒè³Šåœ¢å€ïŒ 10 4.9% 9 4.2% 0.7%
ã¯ãã¹ã«ã«ã¡ããŒã¹ãããª
ãŠã ïŒåŽ©å£å€ïŒ
6 3.0% 7 3.3% 0.3%
ã¹ãã¢ãªã³é žãã°ãã·ãŠã
ïŒæ»æ²¢å€ïŒ
2 1.0% 2 0.9% 0.1%
åèš 203 100% 215 100%
å·®ã®åèš%ïŒ 4.3%